Novo Announces U.S. Launch of NovoPen Echo


By: dhtest

Plainsboro, N.J.–Novo Nordisk has announced the U.S. launch of its NovoPen Echo® insulin delivery device. It is the first and only pen device available in this country with half-unit dosing and a memory function that records the dose and time passed since the last injection.

“We believe this pen can help patients fine-tune their dosing while offering added reassurance they are managing their diabetes appropriately,” said George McAvoy, vice president, NovoLog brand team at Novo Nordisk.

Because half-unit dose increments allow for finer adjustments, the device can be particularly useful to children, who often require more closely adjusted dosages. In addition, 12 removable skins are available for a customized look, including kid-friendly designs.

Jeff Hitchcock, founder of Children with Diabetes, said the device “is a welcome addition to the tools children with diabetes and their caregivers have available, especially when kids are away from home.”

The new pen is available to patients for use with NovoLog® PenFill® cartridges. Novo Nordisk has already launched NovoPen Echo® in Europe, Canada, and Israel.

For more information on Novo Nordisk products, visit




Diabetes Health Medical Disclaimer
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.